Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy Participants
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT06566768
- Phase
- PHASE1
- Status
- Completed
Conditions
- Healthy Participants
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Accepted
Interventions
- Deucravacitinib — DRUGSpecified dose on specified days
Study Details
The purpose of this study is to identify drug levels of gastro-retentive (GR) formulations which prolong retaining time in the stomach of deucravacitinib (BMS-986165) in Healthy Participants.
Key Dates
- Start date
- Oct 7, 2024
- Status verified
- Jun 2025
- Primary completion
- Jun 13, 2025
- Completion
- Jun 13, 2025
Study Design
- Enrollment
- 52 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Part A: Deucravacitinib
- Experimental: Part B: Deucravacitinib
Primary Outcome Measure
Maximum observed plasma concentration (Cmax) [ Time Frame: Up to approximately 5 days ]
Related Studies
- A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)PHASE1 · Recruiting · Equilibra Bioscience LLC · Glendale, California
- FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and PatientsPHASE1 · Recruiting · Pfizer · Anaheim, California
- A Study of Oral E1018 in Healthy Adult ParticipantsPHASE1 · Recruiting · Eisai Inc. · Austin, Texas
- A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult ParticipantsPHASE1 · Recruiting · Incyte Corporation · Lincoln, Nebraska